Chronic Heart Failure
Conditions
Keywords
ketosis, beta-hydroxybutyrate, insulin, bioenergetics, exercise tolerance, metabolic, diabetes
Brief summary
Chronic, ambulatory heart failure patients will be given ketone ester dietary supplementation to determine therapeutic efficacy, metabolic adaptation, pharmacokinetics, associated cognitive changes, and safety within this patient cohort in order to establish preliminary data to later conduct a multi-center randomized clinical trial.
Detailed description
We previously demonstrated a metabolic signature of increased ketone utilization-increased peripheral blood concentration of beta-hydroxybutyrate (BHB) and decreased myocardial concentration of BHB-and markedly decreased acylcarnitine levels in the failing human myocardium procured from lean, non-diabetic patients with advanced heart failure at the time of cardiac transplantation. In this working model of the metabolic adaptations in human heart failure where the mobilization of lipids and ketones are required for an energetically deficient, failing heart it is likely that the development of insulin resistance may be adaptive since increased insulin or insulin signaling would put a brake on the hydrolysis of lipids and hepatic ketogenesis. In parallel with the recent discovery that the failing human heart is reliant on ketones, investigators at Oxford and the NIH have identified a nutritional ketone supplement that reliably increases the serum concentration of BHB in humans. We hypothesize that the induction of ketosis by exogenous administration of the nutritional ketone monoester will improve myocardial function in heart failure by increasing the energetic substrate available to the myocardium, in essence supporting the energetic deficit of the failing human heart which we have demonstrated to be reliant on ketone bodies for fuel given the limited myocardial oxidation of glucose. This is a prospective, double-blinded, sequence control crossover trial enrolling NYHA Class II-III ambulatory heart failure patients to receive either ketone mono-ester drink versus placebo for two weeks. Following 2 weeks of therapy, echocardiogram and peak exercise test will be performed. There will be a 1-week washout period between phases. Subjects will serve as their own controls for this crossover study, as each will have both baseline testing and testing in the setting of mild nutritional ketosis.
Interventions
DRUGbeta hydroxybutyrate (BHB) ester
Ketone supplementation given 3x/day (60mL per dose, or 22g BHB)
DRUGPlacebo
Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
Sponsors
Thomas Jefferson University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
Biological drug + placebo (Group A) or placebo + biological drug (Group B)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Equal to or greater than 18 years of age 2. Diagnosis of heart failure and be classified as NYHA Class II or III either pre-enrollment or at the time of enrollment 3. Stable medical therapy for at least 1 month prior to enrollment 4. Taking appropriate daily cardiac medications as determined by the principal investigator, who is a heart failure specialist
Exclusion criteria
1. Atrial fibrillation 2. Inability to exercise on a supine bicycle. 3. Moderate or greater valvular disease. 4. Hemoglobin \<10 g/dL. 5. Daily insulin use 6. Hypertrophic, infiltrative, or inflammatory cardiomyopathy. 7. Pericardial disease. 8. Current angina due to clinically significant obstructive epicardial coronary disease 9. Acute coronary syndrome or coronary intervention within the past 2 months. 10. Primary pulmonary arteriopathy. 11. Known clinically significant lung disease defined as: 1. Current use of supplemental oxygen, aside from nocturnal O2 for the treatment of obstructive sleep apnea 2. The use of steroids/antibiotics within the past 6 months for an acute exacerbation of obstructive pulmonary disease 3. Most proximal pulmonary function test indicating severe obstructive disease, defined as an FEV1\<50% predicted in the context of an FEV1/FVC ratio of \<0.70 (Stage III COPD according to GOLD Criteria). (note: only to be used if the subject had PFTs prior to screening) 4. Most proximal 6-minute walk test during which the subject experienced arterial desaturation (\<94%) without a subsequent normal study. 12. Ischemia on stress testing without subsequent revascularization or left heart catheterization showing non-obstructive epicardial coronary disease. 13. Significant liver disease impacting synthetic function or volume control. 14. Uncontrolled hypertension: BP \>180/110 at baseline. 15. eGFR \<30 mL/min/m2 or Cr \>2.5. 16. Alcohol dependence 17. Chronic narcotic use that cannot be interrupted 18. Pregnant or lactating females
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BHB Concentration in blood | 1 Year | Beta-hydroxybutyrate concentration in blood |
| Minutes at maximum exertion [Exercise Capacity] | 1 Year | Minutes at maximum exertion |
| Left ventricular ejection fraction (%) | 1 Year | Left ventricular ejection fraction, measured by echocardiogram |
| Cardiac output (L/min) | 1 Year | Cardiac output, measured by echocardiogram |
| Left ventricular end diastolic diameter (LVEDD) (cm) | 1 Year | LVEDD, measured by echocardiogram |
| Insulin concentration | 1 Year | Insulin concentration in blood |
| Bicarbonate concentration | 1 Year | Bicarbonate concentration in blood |
Contacts
Primary ContactMichael W Foster, M.D.
Backup ContactMelissa McCarey
Outcome results
None listed